A Phase 2 interventional study of AT-527 and Placebo in COVID-19, sponsored by Hoffmann-La Roche. Completed at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.
Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 116th largest by enrollment of the 172 interventional ones that give a count, is one of 83 that started in 2021, is one of 27 in phase 2, and was the 189th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–50 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in United Kingdom, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
340 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 52 · Phase 3 66 · Phase 4 5
First in 2013; this study’s year is marked. 83 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is close to the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 247 across the 172 interventional studies, 296 across the 167 observational. Of the 245 that completed or were terminated, 75 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 340 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
| NCT04863573Queen's University, BelfastCOVID-19 Antibody Responses In Cystic Fibrosis | 2027-08 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 340 studies in COVID-19 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AT-527-matched placebo twice a day (BID) on Days 1-5.
Drug: Placebo
Participants will receive 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5.
Drug: AT-527
Participants will receive 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.
Drug: AT-527
Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
Also known as: RO7496998
The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 550 mg and Matched Placebo
SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.
Time frame: Baseline, Day 3, Day 5, Day 7
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 1100 mg and Pooled Placebo
SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from NP swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.
Time frame: Baseline, Day 3, Day 5, Day 7
Time to Cessation of SARS-CoV-2 Viral Shedding
Time to cessation of viral shedding was defined as the time between the initiation of any study treatment and the first time when a negative or below the limit of detection RT-PCR test result was obtained. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.
Time frame: Up to Day 7
Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA
Time to sustained non-detectable SARS-CoV-2 virus RNA was defined as the time between the initiation of any study treatment and first time when a negative or below the limit of detection test result by RT-PCR is obtained after which no positive test above or equal to the limit of detection was reported. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.
Time frame: Up to Day 7
Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints
Reported here is the percentage of participants with a positive virus RNA by RT-PCR test result above or equal to the limit of quantification (LOQ). RT-PCR was measured from NP swabs.
Time frame: Baseline, Day 3, Day 5, Day 7
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA
AUC is the amount of SARS-CoV-2 virus RNA from baseline to the last sample timepoint and was calculated using the trapezoidal method. RT-PCR was measured from NP swabs.
Time frame: Baseline, Day 3, Day 5, Day 7
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 21.5 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.
Time frame: Up to 28 Days
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 43 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.
Time frame: Up to 28 Days
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 21.5 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.
Time frame: Up to 28 Days
Time to Alleviation of COVID-19 Symptoms (43 Hours)
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 43 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.
Time frame: Up to 28 Days
Duration of Fever
Duration of fever was defined as the time from start of treatment to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.
Time frame: Up to 28 Days
Percentage of Participants With COVID-19 Related Complications
COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, and cardiac failure.
Time frame: Up to 33 Days
Time to Alleviation of an Individual Symptom
The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 was recorded on a 4-point Likert scale (none=0, mild=1, moderate=2, severe=3). Items 13-14 were recorded on a 3-point Likert scale (same as usual=0, less than usual=1, no sense=2). Time to alleviation of an individual symptom was defined as the time taken from the start of treatment to the point at which the following criterion was met and maintained (for each individual symptom) for at least 21.5 hours: score of 0 or 1 for Items 1-12 of the COVID-19 Symptom Diary; score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary.
Time frame: Up to 28 Days
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention.
Time frame: Up to 33 Days
Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 550 mg AT-527
AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.
Time frame: Day 1: pre-dose, 1 hour, 3 hours; Day 3: pre-dose; Day 5: pre-dose, 3 hours, 48 hours
Plasma Concentrations of AT-511, AT-551, AT-229 and AT-273 for Participants Treated With 1100 mg AT-527
AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.
Time frame: Day 1: pre-dose, 1 hour, 4 hours; Day 3: pre-dose; Day 5: pre-dose, 1 hour, 4 hours, 48 hours
Participants were enrolled in the study at sites in the United Kingdom, Spain, Greece, Latvia, Ireland and Canada.
| Milestone | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Started | 40 | 30 | 30 |
| Completed | 40 | 29 | 30 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.
| log10 copies/mL | Placebo Matched to AT-527 550 mg | AT-527 550 mg (1x550 mg) |
|---|---|---|
| Day 3 | -1.16 ± 0.203 | -1.26 ± 0.206 |
| Day 5 | -2.42 ± 0.230 | -2.11 ± 0.226 |
| Day 7 | -3.13 ± 0.220 | -3.38 ± 0.220 |
Time to cessation of viral shedding was defined as the time between the initiation of any study treatment and the first time when a negative or below the limit of detection RT-PCR test result was obtained. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Cessation of SARS-CoV-2 Viral Shedding | NA (144.2 to NA) | NA (143.8 to NA) | NA (141.1 to NA) |
Time to sustained non-detectable SARS-CoV-2 virus RNA was defined as the time between the initiation of any study treatment and first time when a negative or below the limit of detection test result by RT-PCR is obtained after which no positive test above or equal to the limit of detection was reported. RT-PCR was measured from NP swabs. Median, 25th and 75th percentiles were estimated from the Kaplan-Meier curve.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Reported here is the percentage of participants with a positive virus RNA by RT-PCR test result above or equal to the limit of quantification (LOQ). RT-PCR was measured from NP swabs.
| percentage of participants | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Baseline | 100 | 100 | 96.7 |
| Day 3 | 95.0 | 100 | 93.1 |
| Day 5 | 84.2 | 90.0 | 83.3 |
| Day 7 | 76.9 | 79.3 | 76.7 |
AUC is the amount of SARS-CoV-2 virus RNA from baseline to the last sample timepoint and was calculated using the trapezoidal method. RT-PCR was measured from NP swabs.
| log10 copies/mL*hour | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA | 651.56 ± 189.10 | 733.70 ± 146.63 | 618.62 ± 194.88 |
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 21.5 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours) | 43.4 (9.3 to 104.7) | 57.2 (9.0 to 115.8) | 56.4 (2.5 to 96.4) |
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation or improvement is defined as the length of time taken from start of treatment to the point at which all of the following three criteria are met and maintained for a concurrent duration of at least 43 hours: "new" symptoms with a score of 0 or 1; "pre- existing and worsened due to COVID-19" symptoms with at least a single category improvement from baseline; "pre-existing and not worsened due to COVID-19" symptoms remaining the same or at least a single category improvement from baseline.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours) | 43.4 (9.3 to 104.7) | 57.2 (9.0 to 141.2) | 58.1 (2.5 to 118.2) |
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 21.5 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Alleviation of COVID-19 Symptoms (21.5 Hours) | 43.4 (9.3 to 104.7) | 57.2 (9.0 to 115.8) | 56.4 (8.2 to 96.4) |
COVID-19 symptoms were evaluated using the first 12 items in the COVID-19 Symptom Diary, which included the following 12 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, and diarrhea. The symptoms were scored on the 4-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). Time to alleviation of COVID-19 symptoms is defined as the length of time taken from start of treatment to the point at which the following criterion is met and maintained for at least 43 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary, regardless of if the symptom is pre-existing or new.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Time to Alleviation of COVID-19 Symptoms (43 Hours) | 43.4 (9.3 to 104.7) | 57.2 (9.0 to 141.2) | 58.1 (8.2 to 118.2) |
Duration of fever was defined as the time from start of treatment to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Duration of Fever | 10.6 (9.6 to 11.7) | — | — |
COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, and cardiac failure.
| percentage of participants | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Percentage of Participants With COVID-19 Related Complications | 0 | 3.3 | 3.3 |
The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 was recorded on a 4-point Likert scale (none=0, mild=1, moderate=2, severe=3). Items 13-14 were recorded on a 3-point Likert scale (same as usual=0, less than usual=1, no sense=2). Time to alleviation of an individual symptom was defined as the time taken from the start of treatment to the point at which the following criterion was met and maintained (for each individual symptom) for at least 21.5 hours: score of 0 or 1 for Items 1-12 of the COVID-19 Symptom Diary; score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary.
| hours | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Nasal Congestion/Runny Nose | 27.6 (11.3 to 59.9) | 34.2 (15.8 to 82.4) | 32.7 (10.0 to 57.7) |
| Sore Throat | 20.5 (14.1 to 22.7) | 24.1 (9.8 to 45.0) | 111.7 (22.1 to 201.4) |
| Cough | 22.6 (11.8 to 129.3) | 90.7 (23.7 to 140.4) | 33.9 (20.5 to 119.2) |
| Shortness of Breath | 23.9 (11.5 to NA) | 68.9 (68.5 to 69.2) | 11.6 (11.6 to 11.6) |
| Aches and Pains | 33.1 (11.8 to 60.4) | 22.3 (16.3 to 62.2) | 94.4 (48.1 to 177.7) |
| Fatigue | 47.8 (22.6 to 178.1) | 44.4 (10.5 to 94.5) | 70.6 (22.6 to 106.0) |
| Headache | 32.0 (10.1 to 95.8) | 11.7 (9.8 to 93.6) | 34.4 (21.8 to 105.4) |
| Chills/Sweats | 11.8 (9.8 to 24.1) | 12.0 (9.0 to 35.8) | 25.0 (17.1 to 41.4) |
| Feeling Hot or Feverish | 26.5 (11.8 to 35.7) | 48.0 (24.0 to 72.0) | 40.3 (15.9 to 63.4) |
| Nausea | NA (21.1 to NA) | — | — |
| Vomiting | NA (11.0 to NA) | — | — |
| Diarrhea | NA (NA to NA) | — | 9.8 (9.8 to 9.8) |
| Sense of Smell | 261.5 (164.9 to NA) | 290.2 (130.7 to NA) | 213.1 (129.7 to 513.7) |
| Sense of Taste | 221.1 (165.3 to 297.6) | 214.1 (94.1 to NA) | 178.5 (105.5 to 391.2) |
An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention.
| percentage of participants | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 27.5 | 20.0 | 33.3 |
AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.
| nanograms per milliliter (ng/mL) | AT-527 550 mg (1x550 mg) |
|---|---|
| AT-511: Day 1, pre-dose | 1.3 ± 4.5 |
| AT-511: Day 1, 1 hour | 1950.5 ± 2365.0 |
| AT-511: Day 1, 3 hours | 441.4 ± 645.8 |
| AT-511: Day 3, pre-dose | 254.2 ± 943.1 |
| AT-511: Day 5, pre-dose | 5.6 ± 21.9 |
| AT-511: Day 5, 3 hours | 415.7 ± 445.5 |
| AT-511: Day 5, 48 hours | 0.5 ± 0.0 |
| AT-551: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-551: Day 1, 1 hour | 347.5 ± 334.1 |
| AT-551: Day 1, 3 hours | 375.8 ± 303.9 |
| AT-551: Day 3, pre-dose | 56.9 ± 100.1 |
| AT-551: Day 5, pre-dose | 26.6 ± 22.7 |
| AT-551: Day 5, 3 hours | 323.8 ± 168.3 |
| AT-551: Day 5, 48 hours | 1.7 ± 1.4 |
| AT-229: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-229: Day 1, 1 hour | 268.5 ± 318.5 |
| AT-229: Day 1, 3 hours | 427.4 ± 275.8 |
| AT-229: Day 3, pre-dose | 290.3 ± 152.3 |
| AT-229: Day 5, pre-dose | 295.4 ± 145.0 |
| AT-229: Day 5, 3 hours | 773.9 ± 340.8 |
| AT-229: Day 5, 48 hours | 89.2 ± 87.8 |
| AT-273: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-273: Day 1, 1 hour | 26.5 ± 29.0 |
| AT-273: Day 1, 3 hours | 132.2 ± 66.7 |
| AT-273: Day 3, pre-dose | 135.9 ± 47.6 |
| AT-273: Day 5, pre-dose | 138.1 ± 53.0 |
| AT-273: Day 5, 3 hours | 236.9 ± 79.9 |
| AT-273: Day 5, 48 hours | 40.9 ± 22.7 |
AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT-273.
| nanograms per milliliter (ng/mL) | AT-527 1100 mg (4x275 mg) |
|---|---|
| AT-511: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-511: Day 1, 1 hour | 3575.0 ± 2883.6 |
| AT-511: Day 1, 4 hours | 852.4 ± 1513.2 |
| AT-511: Day 3, pre-dose | 9.6 ± 15.9 |
| AT-511: Day 5, pre-dose | 316.7 ± 1544.7 |
| AT-511: Day 5, 1 hour | 3568.9 ± 3352.1 |
| AT-511: Day 5, 4 hours | 1323.3 ± 2883.5 |
| AT-511: Day 5, 48 hours | 0.6 ± 0.6 |
| AT-551: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-551: Day 1, 1 hour | 592.2 ± 576.9 |
| AT-551: Day 1, 4 hours | 640.4 ± 446.3 |
| AT-551: Day 3, pre-dose | 84.0 ± 72.1 |
| AT-551: Day 5, pre-dose | 71.3 ± 61.6 |
| AT-551: Day 5, 1 hour | 302.8 ± 222.1 |
| AT-551: Day 5, 4 hours | 342.1 ± 254.9 |
| AT-551: Day 5, 48 hours | 4.4 ± 4.8 |
| AT-229: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-229: Day 1, 1 hour | 371.9 ± 460.3 |
| AT-229: Day 1, 4 hours | 865.4 ± 494.2 |
| AT-229: Day 3, pre-dose | 682.8 ± 351.7 |
| AT-229: Day 5, pre-dose | 797.8 ± 459.9 |
| AT-229: Day 5, 1 hour | 990.9 ± 505.3 |
| AT-229: Day 5, 4 hours | 1357.2 ± 825.3 |
| AT-229: Day 5, 48 hours | 279.4 ± 285.3 |
| AT-273: Day 1, pre-dose | 0.5 ± 0.0 |
| AT-273: Day 1, 1 hour | 35.7 ± 47.4 |
| AT-273: Day 1, 4 hours | 231.8 ± 111.4 |
| AT-273: Day 3, pre-dose | 245.6 ± 122.8 |
| AT-273: Day 5, pre-dose | 263.6 ± 107.3 |
| AT-273: Day 5, 1 hour | 252.1 ± 97.4 |
| AT-273: Day 5, 4 hours | 310.6 ± 107.5 |
| AT-273: Day 5, 48 hours | 84.4 ± 45.5 |
SARS-CoV-2 virus RNA was measured by reverse-transcription polymerase chain reaction (RT-PCR) from NP swabs. The change from baseline was estimated from an ANCOVA model with baseline viral load as a covariate. Reported here is the adjusted mean change from baseline. A negative change from baseline indicates an improvement.
| log10 copies/mL | Pooled Placebo | AT-527 1100 mg (4x275 mg) |
|---|---|---|
| Day 3 | -1.08 ± 0.190 | -1.18 ± 0.223 |
| Day 5 | -2.21 ± 0.205 | -2.31 ± 0.231 |
| Day 7 | -2.70 ± 0.207 | -2.78 ± 0.236 |
Collected over Up to 33 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pooled Placebo | 0/40 (0%) | 1/40 (2.5%) | 1/40 (2.5%) |
| AT-527 550 mg (1x550 mg) | 0/30 (0%) | 1/30 (3.3%) | 1/30 (3.3%) |
| AT-527 1100 mg (4x275 mg) | 0/30 (0%) | 1/30 (3.3%) | 5/30 (16.7%) |
| Event | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/40 | 1/30 | 1/30 |
| Atrial flutterCardiac disorders | 1/40 | 0/30 | 0/30 |
| Event | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) |
|---|---|---|---|
| VomitingGastrointestinal disorders | 1/40 | 0/30 | 5/30 |
| NauseaGastrointestinal disorders | 1/40 | 1/30 | 3/30 |
The modified ITT infected (mITTi) population was defined as all participants randomized in the study who received any amount of study drug and had at least one positive SARS-CoV-2 RT-PCR test result above or equal to the limit of quantification (LOQ) during the study, with participants grouped according to the treatment assignment at randomization.
| Age, Continuous(years) | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) | Total |
|---|---|---|---|---|
| Mean | 36.8 ± 13.2 | 32.7 ± 10.9 | 40.3 ± 15.6 | 36.6 ± 13.6 |
| Sex: Female, Male(Participants) | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) | Total |
|---|---|---|---|---|
| Female | 22 | 15 | 17 | 54 |
| Male | 18 | 15 | 13 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 1 | 8 |
| Not Hispanic or Latino | 36 | 26 | 29 | 91 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 3 |
| White | 38 | 29 | 28 | 95 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA at Baseline(log10 copies/mL) | Pooled Placebo | AT-527 550 mg (1x550 mg) | AT-527 1100 mg (4x275 mg) | Total |
|---|---|---|---|---|
| Mean | 6.24 ± 1.40 | 6.98 ± 1.10 | 5.94 ± 1.46 | 6.37 ± 1.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)
Ran from Feb 2021 to primary completion in Sep 2021, 7 months.
Results were first posted in Oct 2022, 1 year after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 7 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bemnifosbuvir